Clinic trial of combination therapy with Autologous hematopoietic stem cell transplantation and artificial liver system for the liver failure patients

Clinic trial of ombination therapy with Autologous hematopoietic stem cell transplantation and artificial liver system for the liver failure patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12003518

Enrollment

Unknown

Registered

2012-03-21

Start date

2012-05-31

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV-related acute-on-chronic liver failure

Interventions

1:Routine supportive care +PBHSCT+PE

2:Routine supportive care +C-GSF

3:Routine supportive care +PE

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Signed the informed consent form before participation; 2. Between 18 and 65 years old; 3. Serum HBsAg (+); 4. chronic-on-acute liver failure; 5. Peripheral blood WBC>3.0×10^9/L.

Exclusion criteria

Exclusion criteria: 1. complicated with other virus infection (HAV, HCV, HDV, HEV, CMV, EBV and HIV); 2. Primary liver cancer; 3. Exists any other severe active physical or mental diseases, including uncontrolled clinically significant primary renal, cardiac, pulmonary, vascular, nervous, digestive, metabolic diseases, immune deficiency, and cancer; 4. Creatinine > 133 umo1/L; 5. Existence of uncontrolled severe infection; 6. Shock; 7. Active gastrointestinal bleeding 8. Highly allergic to plasma, heparin, and protamine,

Design outcomes

Primary

Measure	Time frame
Survial Time and Survival Rate;liver function indicators;PTA;Urea;	—

Countries

China

Contacts

Public ContactShaojie Xin

xsj302@yahoo.com.cn+86 010-66933434

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026